Stay updated on Elranatamab in Refractory Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the Elranatamab in Refractory Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Elranatamab in Refractory Multiple Myeloma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The website footer now identifies the site as running revision v3.8.0 instead of v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-31T13:21:18.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The trial record now reports the study as completed and no longer seeking participants, with a new record version that updates study status and contact/location information.
    Difference
    0.7%
    Check dated 2026-10-24T13:47:00.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-17T13:46:30.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.1%
    Check dated 2026-10-10T14:47:47.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The study record history shows an update from Revision: v3.6.6 to Revision: v3.7.0, indicating a system/version update to the page display without changing the underlying study information.
    Difference
    0.1%
    Check dated 2026-09-19T21:59:17.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The page's Revision label changed from v3.6.5 to v3.6.6 on the Record History page.
    Difference
    0.1%
    Check dated 2026-08-29T21:56:33.000Z thumbnail image

Stay in the know with updates to Elranatamab in Refractory Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Elranatamab in Refractory Multiple Myeloma Clinical Trial page.